SEHK:157

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Natural Beauty Bio-Technology

Market Cap

HK$1.3b

Last Updated

2021/07/29 16:22 UTC

Data Sources

Company Financials

Executive Summary

Natural Beauty Bio-Technology Limited, an investment holding company, manufactures and sells skin care, beauty, aroma-therapeutic, and health supplements and make-up products under the Natural Beauty brand in the People’s Republic of China, Taiwan, and internationally. More Details


Snowflake Analysis

Excellent balance sheet with weak fundamentals.

Share Price & News

How has Natural Beauty Bio-Technology's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 157 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: 157's weekly volatility (7%) has been stable over the past year.


Market Performance


7 Day Return

-5.6%

157

-3.7%

HK Personal Products

-4.3%

HK Market


1 Year Return

n/a

157

-3.0%

HK Personal Products

8.2%

HK Market

Return vs Industry: Insufficient data to determine how 157 performed against the Hong Kong Personal Products industry.

Return vs Market: Insufficient data to determine how 157 performed against the Hong Kong Market.


Shareholder returns

157IndustryMarket
7 Day-5.6%-3.7%-4.3%
30 Day-4.3%-8.0%-9.4%
90 Day-2.9%2.0%-9.8%
1 Yearn/a1.4%-3.0%12.0%8.2%
3 Year-14.5%-16.3%0.3%-10.2%10.0%-2.3%
5 Year18.2%-8.2%-0.8%-16.5%38.9%14.3%

Long-Term Price Volatility Vs. Market

How volatile is Natural Beauty Bio-Technology's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Natural Beauty Bio-Technology undervalued compared to its fair value and its price relative to the market?

172.95x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: 157 (HK$0.67) is trading above our estimate of fair value (HK$0.03)

Significantly Below Fair Value: 157 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 157 is poor value based on its PE Ratio (172.9x) compared to the Hong Kong Personal Products industry average (6.8x).

PE vs Market: 157 is poor value based on its PE Ratio (172.9x) compared to the Hong Kong market (10.6x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 157's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 157 is overvalued based on its PB Ratio (2.2x) compared to the HK Personal Products industry average (0.7x).


Future Growth

How is Natural Beauty Bio-Technology forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

18.1%

Forecasted Household industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Natural Beauty Bio-Technology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Natural Beauty Bio-Technology performed over the past 5 years?

-47.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 157 has a large one-off loss of HK$2.7M impacting its December 31 2020 financial results.

Growing Profit Margin: 157's current net profit margins (1.9%) are lower than last year (5%).


Past Earnings Growth Analysis

Earnings Trend: 157's earnings have declined by 47.8% per year over the past 5 years.

Accelerating Growth: 157's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 157 had negative earnings growth (-64.4%) over the past year, making it difficult to compare to the Personal Products industry average (-8%).


Return on Equity

High ROE: 157's Return on Equity (1.3%) is considered low.


Financial Health

How is Natural Beauty Bio-Technology's financial position?


Financial Position Analysis

Short Term Liabilities: 157's short term assets (HK$400.5M) exceed its short term liabilities (HK$204.7M).

Long Term Liabilities: 157's short term assets (HK$400.5M) exceed its long term liabilities (HK$16.1M).


Debt to Equity History and Analysis

Debt Level: 157's debt to equity ratio (11%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if 157's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: 157's debt is well covered by operating cash flow (44.6%).

Interest Coverage: 157 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Natural Beauty Bio-Technology current dividend yield, its reliability and sustainability?

0.45%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: 157's dividend (0.45%) isn’t notable compared to the bottom 25% of dividend payers in the Hong Kong market (2.12%).

High Dividend: 157's dividend (0.45%) is low compared to the top 25% of dividend payers in the Hong Kong market (6.58%).


Stability and Growth of Payments

Stable Dividend: 157 is not paying a notable dividend for the Hong Kong market, therefore no need to check if payments are stable.

Growing Dividend: 157 is not paying a notable dividend for the Hong Kong market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: 157 is not paying a notable dividend for the Hong Kong market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 157's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.8yrs

Average management tenure


CEO

Yen-Ling Lin (58 yo)

2.75yrs

Tenure

HK$3,119,000

Compensation

Ms. Lin Yen-Ling has been Chief Executive Officer of Natural Beauty Bio-Technology Limited since October 26, 2018. She has been working in Eastern Group since May 2018 as Chief Marketing & Sales Officer of...


CEO Compensation Analysis

Compensation vs Market: Yen-Ling's total compensation ($USD400.94K) is above average for companies of similar size in the Hong Kong market ($USD286.09K).

Compensation vs Earnings: Yen-Ling's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: 157's management team is considered experienced (2.8 years average tenure).


Board Members

Experienced Board: 157's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Natural Beauty Bio-Technology Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Natural Beauty Bio-Technology Limited
  • Ticker: 157
  • Exchange: SEHK
  • Founded: 1972
  • Industry: Personal Products
  • Sector: Household
  • Market Cap: HK$1.341b
  • Shares outstanding: 2.00b
  • Website: https://www.nblife.com

Number of Employees


Location

  • Natural Beauty Bio-Technology Limited
  • Hopewell Centre
  • Level 54
  • Wan Chai
  • Hong Kong

Listings


Biography

Natural Beauty Bio-Technology Limited, an investment holding company, manufactures and sells skin care, beauty, aroma-therapeutic, and health supplements and make-up products under the Natural Beauty brand...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/07/29 16:22
End of Day Share Price2021/07/29 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.